Pulmonary Cell News Volume 9.31 | Aug 13 2020

    By
    Justin.choi
    -
    0
    23







    2020-08-13 | PULCN 9.31


    Pulmonary Cell News by STEMCELL Technologies
    Vol. 9.31 – 13 August, 2020
    TOP STORY

    Hederagenin Potentiated Cisplatin- and Paclitaxel-Mediated Cytotoxicity by Impairing Autophagy in Lung Cancer Cells

    Investigators observed that hederagenin induced the increased autophagosomes in lung cancer cells concomitantly with the upregulation of LC3-II and p62, which indicated the impairment of autophagic flux.
    [Cell Death & Disease]

    Full Article

    Scientific resources to support your organoids research. Learn More!
    PUBLICATIONSRanked by the impact factor of the journal

    Neutrophil Extracellular Traps Amplify Neutrophil Recruitment and Inflammation in Neutrophilic Asthma by Stimulating the Airway Epithelial Cells to Activate the TLR4/NF-κB Pathway and Secrete Chemokines

    Formation of neutrophil extracellular traps (NETs) and neutrophil swarming was seen in a mouse model of neutrophilic asthma. Additionally, NETs were found to stimulate airway cells to express CXCL1, CXCL2, and CXCL8 via the TLR4/NF-κB pathway, which recruited neutrophils to the inflammation site.
    [Aging]

    Full Article

    Prenatal Smoke Exposure Dysregulates Lung Epithelial Cell Differentiation in Mouse Offspring – Role for AREG-Induced EGFR Signaling

    Scientists investigated the effect of prenatal smoke exposure on lung epithelial cell differentiation and linked this with Amphiregulin-epidermal growth factor receptor signaling in one-day old mouse offspring.
    [American Journal of Physiology-Lung Cellular and Molecular Physiology]

    Abstract

    DMBT1 Is Up‐Regulated in Lung Epithelial Cells after Hypoxia and Changes Surfactant Ultrastructure

    Deleted in malignant brain tumors 1 (DMBT1) expression was up‐regulated in human lung tissue after fetal/peri‐/postnatal hypoxia. Additionally, in vitro experiments showed increased DMBT1 RNA expression in A549 cells after hypoxia.
    [Pediatric Pulmonology]

    Abstract

    Mex3a Interacts with LAMA2 to Promote Lung Adenocarcinoma Metastasis via PI3K/AKT Pathway

    Researchers demonstrated that Mex3a knockdown significantly inhibited lung adenocarcinoma cell migration and invasion in vitro and metastasis in nude mice.
    [Cell Death & Disease]

    Full Article

    DRP1 Promotes Lactate Utilization in KRAS‐Mutant Non‐Small Cell Lung Cancer Cells

    Scientists developed a lactate‐dependent cell proliferation assay and found that dynamin‐related protein (DRP1), which was highly expressed in KRAS‐mutant non‐small cell lung cancer (NSCLC), was required for tumor cells to proliferate and used lactate as fuel, demonstrating the critical role of DRP1 in the metabolic reprogramming of NSCLC.
    [Cancer Science]

    Abstract

    circRACGAP1 Promotes Non-Small Cell Lung Cancer Proliferation by Regulating miR-144-5p/CDKL1 Signaling Pathway

    Expression patterns of circRACGAP1 and miR-144-5p in non-small cell lung cancer tissues and cell lines were quantified by qRT-PCR analysis. Then, the function of circRACGAP1 on cell proliferation and tumorigenesis were confirmed in vitro and in vivo using CCK-8 assay, colony formation, EdU incorporation, and xenograft technique.
    [Cancer Gene Therapy]

    Abstract

    FGL1 Regulates Acquired Resistance to Gefitinib by Inhibiting Apoptosis in Non-Small Cell Lung Cancer

    Scientists investigated the role of fibrinogen-like protein 1 (FGL1) in regulating gefitinib resistance of PC9/GR non-small cell lung cancer.
    [Respiratory Research]

    Full Article

    Luteolin Enhances TRAIL Sensitivity in Non-Small Cell Lung Cancer Cells through Increasing DR5 Expression and Drp1-Mediated Mitochondrial Fission

    Researchers sought to investigate the potential effects of luteolin as a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sensitizer in non-small cell lung cancer cells.
    [Archives of Biochemistry and Biophysics]

    Abstract

    High Expression of NEK2 Promotes Lung Cancer Progression and Drug Resistance and Is Regulated by Mutant EGFR

    Elevated never in mitosis gene A-related kinase 2 level promoted the rapid cell cycle progression and favored the rapid proliferation of epidermal growth factor receptor-mutant non-small cell lung cancer cells.
    [Molecular and Cellular Biochemistry]

    Abstract

    Inhibitory Effect of MicroRNA-608 on Lung Cancer Cell Proliferation, Migration, and Invasion by Targeting BRD4 through the JAK2/STAT3 Pathway

    Investigators determined the fundamental mechanism of microRNA-608 in the development of lung cancer.
    [Bosnian Journal of Basic Medical Sciences]

    Abstract

    Tools and products for your COVID-19 research.
    REVIEWS

    The Potent Roles of Salt-Inducible Kinases (SIKs) in Metabolic Homeostasis and Tumorigenesis

    The authors comprehensively summarize the emerging upstream regulators, downstream substrates, mouse models, clinical relevance, and candidate inhibitors for SIKs, and shed light on SIKs as the potential therapeutic targets for cancer therapies.
    [Signal Transduction and Targeted Therapy]

    Full Article

    INDUSTRY AND POLICY NEWS

    Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer

    Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration with AstraZeneca to evaluate the combination of patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate, and TAGRISSO, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.
    [Daiichi Sankyo Company, Limited]

    Press Release

    Phase III InPedILD™ Trial Enrolls First Patient to Evaluate Nintedanib in Pediatric Population with Fibrosing Interstitial Lung Disease

    Boehringer Ingelheim announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease.
    [Boehringer Ingelheim International GmbH]

    Press Release

    Arrowhead Pharmaceuticals Initiates Dosing Phase I/II Study of ARO-ENaC for Treatment of Cystic Fibrosis

    Arrowhead Pharmaceuticals Inc. announced that it has dosed the first subjects in AROENaC1001, a Phase I/II clinical study of ARO-ENaC, the company’s investigational RNA interference therapeutic being developed as a treatment for patients with cystic fibrosis, which is a rare disease caused by genetic mutations that lead to progressive deterioration in lung function due to poor clearance of mucus and associated recurrent infections.
    [Arrowhead Pharmaceuticals Inc.]

    Press Release

    FEATURED EVENT

    NCRI 2020: Virtual Showcase

    November 2 – November 3
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Lung Regeneration and Pollution

    Institut Mondor de Recherche Biomédicale – Creteil, France

    Assistant Professors – Respiratory Translational Research

    University of British Columbia – Vancouver, British Columbia, Canada

    Postdoctoral Fellowship – Computational Medicine of the Lungs

    Institute for Computational Medicine – Baltimore, Maryland, United States

    Postdoctoral Position – Pluripotent Stem Cell-Derived Human Lung Organoids

    Columbia University Medical Center – New York, New York, United States

    Postdoctoral Research Fellow – Biology of Small Cell Lung Cancer

    Fred Hutchinson Cancer Research Center – Seattle, Washington, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Pulmonary Cell News Twitter